FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C	20549
vasilington,	D.C.	20049

neck this box if no longer subject
Section 16. Form 4 or Form 5
ligations may continue. See
- 4 ··· · - 4 · · · · · · · · · · · · ·

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  YANCOPOULOS GEORGE						RE	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ]									5. Relationship of Reporti (Check all applicable) X Director			10% Ov	vner
(Last)		(Firs	t) (I L RIVER ROA	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/02/2024									belov	er (give title v) Co-Chair, I	Preside	Other (s below) ent & CS	
(Street) TARRYT	TOWN	NY	1	0591		4. If <i>I</i>	Amend	ment,	Date o	f Origina	al Filed	d (Month/Da	y/Year	)	6. Ind Line)	Form	filed by On- filed by Moon	e Repor	ting Perso	on
(City)		(Stat	te) (2	Zip)		Rule 10b5-1(c)				Transaction Indication										
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														nded to						
4 TW55	Na a unite : 41	lu e t		I - Noi	1		_			uired,	Dis	posed of				1		6 0	orobin I.	7 Noture
			Date	2. Transaction Date (Month/Day/Year)			Execution Date,			4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			, 4 and Securi Benefi		ties cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										Code	v	Amount	(A) (D)	or I	Price	Transa	ction(s) 3 and 4)			(111341. 4)
Common Stock 01/0				01/02/2	2024				S <sup>(1)</sup>		16,848	I		\$900	18	180,000		I :	By Trust for Chldn. <sup>(2)</sup>	
Common	Stock															75	2,486	1	D	
Common Stock													5,889			I d	By 401(k) Plan			
Common Stock															121,071				by 2022 GRAT I	
Common Stock													158,410				by 2022 GRAT II			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any					Transaction Code (Instr.		of		Exerci ion Da Day/Y		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (Ir	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y O Fo O (I)	o. wnership orm: irect (D) r Indirect i (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	(A)	(D)			Expiration Date	Title	Amo or Num of Shar	ber					

## **Explanation of Responses:**

- 1. Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022.
- 2. As investment trustee of trusts for the benefit of the reporting person's children.

/s/\*\*George D. Yancopoulos 01/04/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.